UBS Group AG Purchases 102,021 Shares of Genmab A/S Sponsored ADR $GMAB

UBS Group AG boosted its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 124.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 184,191 shares of the company’s stock after buying an additional 102,021 shares during the quarter. UBS Group AG’s holdings in Genmab A/S were worth $5,673,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sanctuary Advisors LLC lifted its position in shares of Genmab A/S by 18.7% during the 4th quarter. Sanctuary Advisors LLC now owns 68,758 shares of the company’s stock worth $2,118,000 after purchasing an additional 10,843 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Genmab A/S by 29.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,525 shares of the company’s stock valued at $293,000 after buying an additional 2,175 shares during the last quarter. M&T Bank Corp increased its position in Genmab A/S by 88.8% in the 4th quarter. M&T Bank Corp now owns 15,034 shares of the company’s stock worth $463,000 after buying an additional 7,073 shares during the period. Eagle Global Advisors LLC lifted its holdings in shares of Genmab A/S by 2.0% during the fourth quarter. Eagle Global Advisors LLC now owns 249,310 shares of the company’s stock worth $7,679,000 after buying an additional 4,840 shares during the last quarter. Finally, Evergreen Capital Management LLC lifted its holdings in shares of Genmab A/S by 14.0% during the fourth quarter. Evergreen Capital Management LLC now owns 22,350 shares of the company’s stock worth $688,000 after buying an additional 2,752 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Up 6.0%

NASDAQ GMAB opened at $27.21 on Thursday. Genmab A/S Sponsored ADR has a 1-year low of $20.23 and a 1-year high of $35.43. The company has a market capitalization of $16.97 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 1.55 and a beta of 0.86. The stock’s 50 day moving average is $26.99 and its two-hundred day moving average is $29.72. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 18th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a return on equity of 15.34% and a net margin of 21.05%. Equities analysts forecast that Genmab A/S Sponsored ADR will post 1.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price objective on the stock. HC Wainwright cut their target price on shares of Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. Guggenheim reduced their price target on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, February 23rd. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.07.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.